Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 May;45(5):690-696.
doi: 10.3899/jrheum.171087. Epub 2018 Feb 1.

Barriers to Adherence in Juvenile Idiopathic Arthritis: A Multicenter Collaborative Experience and Preliminary Results

Leslie A Favier  1   2 , Janalee Taylor  3   4 , Kristin Loiselle Rich  3   4 , Karla B Jones  3   4 , Sheetal S Vora  3   4 , Julia G Harris  3   4 , Beth S Gottlieb  3   4 , Lisa Robbins  3   4 , Jamie T Lai  3   4 , Tzielan Lee  3   4 , Melanie Kohlheim  3   4 , Jennifer Gill  3   4 , Laura Bouslaugh  3   4 , Angela Young  3   4 , Nancy Griffin  3   4 , Esi M Morgan  3   4 , Avani C Modi  3   4
Affiliations
Multicenter Study

Barriers to Adherence in Juvenile Idiopathic Arthritis: A Multicenter Collaborative Experience and Preliminary Results

Leslie A Favier et al. J Rheumatol. 2018 May.

Abstract

Objective: Nonadherence is currently an underrecognized and potentially modifiable obstacle to care in juvenile idiopathic arthritis (JIA). The purpose of our study was to design and implement a standardized approach to identifying adherence barriers for youth with JIA across 7 pediatric rheumatology clinics through the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) and to assess the frequency of adherence barriers in patients and their caregivers across treatment modalities.

Methods: An iterative process using coproduction among parents and providers of patients with JIA was used to design the Barriers Assessment Tool to screen for adherence barriers across 4 treatment modalities (i.e., oral medications, injectable medications, infusions, and physical/occupational therapy). This tool was implemented in 7 rheumatology clinics across the United States and patient responses were collected for analysis.

Results: Data were collected from 578 parents and 99 patients (n = 44 parent-child dyads). Seventy-seven percent (n = 444) of caregivers and 70% (n = 69) of patients reported at least 1 adherence barrier across all treatment components. The most commonly reported adherence barriers included worry about future consequences of therapy, pain, forgetting, side effects, and embarrassment related to the therapy. There was no significant difference between endorsement of barriers between parents and adolescents.

Conclusion: Implementing a standardized tool assessing adherence barriers in the JIA population across multiple clinical settings is feasible. Systematic screening sheds light on the factors that make adherence difficult in JIA and identifies targets for future adherence interventions in clinical practice.

Keywords: JUVENILE ARTHRITIS; PATIENT COMPLIANCE; QUALITY IMPROVEMENT.

PubMed Disclaimer

Conflict of interest statement

There are no other financial supports or other benefits from commercial sources for the work reported in this manuscript. There are no financial interests or disclosures to report on behalf of any of the listed authors that would create a conflict of interest or the appearance of conflict of interest with regard to the work.

Figures

Figure 1
Figure 1
a and b Frequency of Parental Endorsed Barriers across Treatment Modalities. This bar graph indicates the percentages of adherence barriers endorsed on the barriers assessment tool among parental respondents.
Figure 2
Figure 2
a and b Frequency of Patient Endorsed Barriers across Treatment Modalities. This bar graph indicates the percentages of adherence barriers endorsed on the barriers assessment tool among patient respondents.
See this image and copyright information in PMC

Comment in

References

    1. Petty RE, Cassidy JT. Texbook of Pediatric Rheumatology. Elsevier Health Sciences; 2011. Textbook of Pediatric Rheumatology; pp. 262–271.
    1. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117. - PMC - PubMed
    1. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367:2385–2395. - PubMed
    1. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987–1994. - PubMed
    1. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–820. - PubMed

Publication types

Substances